title: D-penicillamine treatment for lipoid proteinosis.
abstract: Lipoid proteinosis, a rare disorder inherited in an autosomal recessive fashion, is characterized by the deposition of hyaline-like material in the skin, mucous membranes, and other tissues. Perturbation of collagen metabolism has been suggested to play an important role in the pathogenesis. No effective therapy is available for the disease. The chelating agent D-penicillamine has long been used to treat several diseases. In addition to its immunosuppressive and anti-inflammatory effects, it also impairs fibroblast proliferation and inhibits the formation of the cross-links in collagen and elastin fibers. A 13-year-old girl was clinically and histologically diagnosed with lipoid proteinosis. We treated her with 600 mg/day of D-penicillamine for 2 years. The patient had improved clinically and histopathologically by the end of this treatment. We suggest D-penicillamine as a promising agent, even in low doses, for the treatment of lipoid proteinosis.
authors.affiliation: Departments of Dermatology and Pathology, Mersin University, School of Medicine, Mersin, Turkey. tikaya@mersin.edu.tr
authors.forename: Tamer Irfan
authors.initials: TI
authors.lastname: Kaya
authors.forename: Aysin
authors.initials: A
authors.lastname: Kokturk
authors.forename: Umit
authors.initials: U
authors.lastname: Tursen
authors.forename: Guliz
authors.initials: G
authors.lastname: Ikizoglu
authors.forename: Ayse
authors.initials: A
authors.lastname: Polat
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D001707:Biopsy, Needle; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008065:Lipoid Proteinosis of Urbach and Wiethe / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D010396:Penicillamine / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D010396:Penicillamine